> On Dec 31, 2015, at 8:48 AM, raghu <[email protected]> wrote:
> 
> On Thu, Dec 31, 2015 at 7:58 AM, Louis Proyect <[email protected]> wrote:
> Leukemia patient Michele Steele ’s doctor prescribed Imbruvica last year
> after she finished her fourth round of chemotherapy. Though shocked at
> the nearly $8,000 out-of-pocket expense for the year, [...]
>  
> [...] But it turned out the couple’s combined income of around $82,000 was 
> just below the cutoff point.
> 
> 
> I will take a contrarian view on this that is sure to be hated by my PEN-L 
> audience.
> 
> Anyone who thinks that being forced to pay $8000 out of a $82,000 income to 
> treat a life-threatening disease is a great human tragedy really needs to go 
> out more.
> -raghu.

This is certainly a contrarian - and wrongheaded - view. It’s common knowledge 
that most of that $8000 is pure profit for the drug companies who spend more on 
marketing than on research and development.

http://www.who.int/trade/glossary/story073/en/

The three major industries urgently crying out for public ownership are energy, 
finance, and pharmaceuticals. 

_______________________________________________
pen-l mailing list
[email protected]
https://lists.csuchico.edu/mailman/listinfo/pen-l

Reply via email to